Related Experiment Video
Updated: Dec 12, 2025
Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
Published on: October 18, 2024
Meta-analysis: Impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity
Olufemi Aoko1,2, Tobias Maharaj1,2, Fiona Boland2
1Hepatology Department, Beaumont Hospital, Dublin, Ireland.
Background:
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease affecting approximately 25% of adults in the western world. Intragastric balloon (IGB) is an endoscopic bariatric therapy -a therapeutic endoscopic tool that has shown promise in inducing weight loss. Its role in the treatment of NAFLD is yet to be established.
Aim:
To evaluate the effect of IGB as a treatment option in NAFLD.
Methods:
We searched MEDLINE (PubMed) and EMBASE from inception to September 2022. We included studies evaluating the impact of IGB on obesity with the assessment of one or more liver-related outcomes and studies primarily evaluating the impact of IGB on NAFLD. We included comparative and non-comparative studies; primary outcomes were liver-related NAFLD surrogates.
Results:
We included 19 studies with 911 patients. IGB demonstrated an effect on NAFLD parameters including NAFLD activity score (NAS): mean difference (MD): -3.0 [95% CI: -2.41 to -3.59], ALT: MD: -10.40 U/L [95% CI: -7.31 to -13.49], liver volume: MD -397.9 [95% CI: -212.78 to 1008.58] and liver steatosis: MD: -37.76 dB/m [95% CI: -21.59 to -53.92]. There were significant reductions in non-liver-related outcomes of body weight, BMI, glycated haemoglobin and HOMA-IR.
Conclusion:
Intragastric balloons may play an important role in addressing the treatment gap in NAFLD management.
